MCL Literature Feed

A targeted NGS panel characterized the mutational landscape of Korean lymphomas, including MCL, demonstrating its utility for identifying clinically relevant mutations like TP53 in diverse subtypes.

This case report documents the rare clinical presentation of mantle cell lymphoma as multiple rectal lesions, highlighting an unusual pattern of gastrointestinal involvement for clinicians to consider.

This conference report identifies key controversies in B-cell lymphoma management, initiating a formal process to develop expert consensus guidelines for navigating increasingly complex treatment selection and sequencing decisions.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

In Chinese patients with relapsed/refractory MCL previously treated with a covalent BTKi, the non-covalent BTKi pirtobrutinib achieved a 62.9% overall response rate, confirming its global efficacy.

A rare composite MCL/LPL case reveals a cryptic IGK::CCND1 fusion driving the MCL, highlighting the diagnostic utility of molecular testing for atypical CCND1 rearrangements.

The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.

This case report describes therapy-related acute megakaryoblastic leukemia after autologous transplant for MCL, highlighting a rare but severe long-term toxicity of intensive consolidation therapy.

This review outlines the evolving MCL treatment paradigm, emphasizing earlier BTKi use, established CAR-T, and emerging non-covalent BTKi and bispecifics for high-risk disease like TP53-mutated MCL.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

An updated indirect comparison suggests zanubrutinib provides significantly longer progression-free survival than orelabrutinib in relapsed/refractory MCL, informing BTKi choice in the absence of head-to-head trial data.

This case report details a rare presentation of MCL transformed to DLBCL with urinary symptoms from prostate involvement, highlighting lymphoma as a differential diagnosis requiring aggressive chemoimmunotherapy and transplant.

This paper describes the high frequency and characteristic patterns of gastrointestinal involvement in MCL, often as lymphomatous polyposis, highlighting the importance of endoscopy for accurate staging.

This review highlights ongoing trials moving CAR-T and bispecific antibodies into earlier lines of MCL therapy, signaling a potential paradigm shift away from traditional chemoimmunotherapy.

This case series reports uveal melanoma development in patients on BTK inhibitors, suggesting a potential rare but serious toxicity and warranting increased ophthalmologic surveillance for this common MCL therapy.

The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.

Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.

This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.

This review advocates for adding a BTKi to frontline immunochemotherapy for transplant-eligible patients as a new standard of care, while also summarizing its emerging role in older patients.

This case report describes the rare anaplastic pleomorphic variant of MCL, highlighting its aggressive features and the critical role of pathology in diagnosing high-risk disease subtypes.

This paper likely characterizes the clinical features, treatment patterns, and poor outcomes of isolated central nervous system relapse in MCL, highlighting a major unmet clinical need.

This case report of synchronous gastric adenocarcinoma and mantle cell lymphoma highlights the need for thorough pathological evaluation of surgical specimens, as MCL can be an incidental finding.

A phase 1 study in Chinese relapsed/refractory B-cell NHL patients establishes the recommended dose of the HDAC inhibitor abexinostat (80 mg BID) with promising activity, supporting further development.

This preclinical study identifies CEACAM1 as a novel activator of B-cell receptor signaling by recruiting SYK, revealing a new potential therapeutic target and mechanism of resistance to BCR inhibitors.

This myeloma review outlines strategies to overcome proteasome inhibitor resistance by targeting other proteostasis pathways, providing a rationale for exploring similar combinations in relapsed/refractory MCL.

The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.

A novel single-cell method integrating biophysical properties with transcriptomics identifies distinct MCL subpopulations, suggesting cell mechanics could be a new biomarker for tumor heterogeneity and therapeutic resistance.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

This preclinical study of a selective immunoproteasome inhibitor in ALL suggests a potential future strategy for MCL to achieve efficacy similar to bortezomib with potentially less off-target toxicity.

This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.